Aggressive B-cell lymphomas (BCL) include both precursor lymphoid neoplasms (B lymphoblastic leukemia/lymphoma NOS and B lymphoblastic leukemia lymphoma with recurrent genetic abnormalities) and ...

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

Lymphoblastic lymphoma largely affects T-cell lymphocytes, a type of cell that works with B-cells to produce antibodies. It usually develops in the mediastinum, causing difficulty breathing and ...

T-cell/histiocyte-rich B-cell lymphoma: A form of DLBCL that has the following characteristics when viewed under a microscope: a few scattered large and atypical B cells; ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

But a certain form of ALL that occurs mostly in babies is still very lethal, with a survival rate below 50 percent: B-cell acute lymphoblastic leukemia with rearrangements of the mixed lineage ...

It is designed to treat lymphoblastic leukaemia and diffuse large B-cell lymphoma. India’s Kauvery Hospital has announced the launch of its CAR-T cell therapy service for certain blood cancers that do ...

Highlights in acute lymphoblastic leukemia from ASH 2021 include pediatric regimens for adults, CNS involvement, and a possible transplant-sparing regimen, as reported by Dr Mark Litzow.

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...

Thus, the clinical advisory committee agreed on the creation of a unifying category designated as “high-grade B-cell lymphoma, with rearrangements of MYC and BCL2 and/or BCL6.” Notably, this category ...

Dhakal P, Kaur J, Gundabolu K, Bhatt VR. Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: ... Leuk Lymphoma. 2020;61:7-17. About Autolus ...